Posted inComunicati
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co.,…
diretta News